share_log

12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga Real-time News ·  Dec 29, 2022 16:32

Gainers

  • Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 53.2% to $0.31 during Thursday's after-market session. Today's trading volume for this security ended up closing at 596.4K shares, which is 76.8 percent of its average volume over the last 100 days. The company's market cap stands at $3.7 million.
  • First Wave BioPharma (NASDAQ:FWBI) stock increased by 22.78% to $0.97. This security traded at a volume of 683.2K shares come close, making up 96.1% of its average volume over the last 100 days. The company's market cap stands at $5.6 million.
  • Soligenix (NASDAQ:SNGX) stock rose 17.61% to $0.53. The market value of their outstanding shares is at $22.9 million.
  • Healthcare Triangle (NASDAQ:HCTI) shares increased by 10.49% to $0.2. The company's market cap stands at $8.3 million.
  • Sientra (NASDAQ:SIEN) shares increased by 9.99% to $0.22. The market value of their outstanding shares is at $22.2 million.
  • Aridis Pharmaceuticals (NASDAQ:ARDS) shares increased by 8.1% to $1.0. The market value of their outstanding shares is at $25.9 million.

Losers

  • Instil Bio (NASDAQ:TIL) stock declined by 7.7% to $0.62 during Thursday's after-market session. The market value of their outstanding shares is at $80.4 million.
  • Aptinyx (NASDAQ:APTX) shares fell 5.75% to $0.31. The market value of their outstanding shares is at $20.9 million.
  • BioLine Rx (NASDAQ:BLRX) stock decreased by 5.68% to $0.54. The market value of their outstanding shares is at $33.2 million.
  • Spectrum Pharmaceuticals (NASDAQ:SPPI) stock decreased by 5.54% to $0.35. The market value of their outstanding shares is at $71.4 million.
  • Vivani Medical (NASDAQ:VANI) stock fell 5.25% to $0.82. The market value of their outstanding shares is at $41.8 million.
  • Taysha Gene Therapies (NASDAQ:TSHA) shares decreased by 5.01% to $2.09. The company's market cap stands at $130.5 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment